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Abstract
Motivation “Molecular signatures” or “gene-expression signatures” are used to predict patients’ charac-
teristics using data from coexpressed genes. Signatures can enhance understanding about biological mech-
anisms and have diagnostic use. However, available methods to search for signatures fail to address key
requirements of signatures, especially the discovery of sets of tightly coexpressed genes.
Results After suggesting an operational definition of signature, we develop a method that fulfills these
requirements, returning sets of tightly coexpressed genes with good predictive performance. This method
can also identify when the data are inconsistent with the hypothesis of a few, stable, easily interpretable sets
of coexpressed genes. Identification of molecular signatures in some widely used data sets is questionable
under this simple model, which emphasizes the needed for further work on the operationalization of the
biological model and the assessment of the stability of putative signatures.
AvailabilityThe code (R with C++) is available from http://www.ligarto.org/rdiaz/Software/Software.html
under the GNU GPL.
Contact rdiaz@cnio.es
Supplementary information http://ligarto.org/rdiaz/Papers/signatures-supl.mat.pdf
1 Introduction
“Molecular signatures” or “gene-expression signatures” are a key feature in many studies that use microarray
data in cancer research (e.g., Alizadeh et al., 2000; Golub et al., 1999; Pomeroy et al., 2002; Rosenwald et al.,
2002; Shipp et al., 2002). Shaffer et al. (2001, p. 375) refer to signatures as “(...) genes that are coordinately
expressed in samples related by some identifiable criterion such as cell type, differentiation state, or signaling
response” (emphasis is ours). Molecular signatures are often used to model patients’ clinically relevant informa-
tion (e.g., prognosis, survival time, etc) as a function of the gene expression data, but instead of using individual
genes as predictors, the predictors are the signature components or “metagenes”.
If we are successful searching for a signature, then we will be able to model, for instance, the probability
of developing a metastasis as a function of a few signature components or metagenes where each signature
component is made of genes that show strong coexpression. Thus, molecular or gene expression signatures
can be important both for diagnostic purposes and for providing information about the biological mechanisms
underlying certain conditions by highlighting genes that both coexpress and are related to that condition.
In spite of the widespread use of the term “molecular signature”, no explicit definition is available. Fol-
lowing the conventions of the literature (e.g., Alizadeh et al., 2000; Golub et al., 1999; Pomeroy et al., 2002;
Rosenwald et al., 2002; Shipp et al., 2002; West et al., 2001), and building upon the definition above (Shaffer et al.,
2001, p. 375), we will consider a signature to be composed of one or more signature components or meta-
genes, where each signature component is a weighted combination of one or more coexpressed genes, and such
that statistical models that use signatures both have good predictive performance and are easy to interpret
biologically. Interpretation is made easier because the prediction is based on signature components that are
weighted averages of subsets of tightly coexpressed genes, which can help when attempting to relate spe-
cific biological features to, for example, particular alterations on a metabolic pathway. Based upon the above
references, we can try to formalize these goals by requiring that signatures and signature components satisfy
the conditions shown in Figure 1.
[Figure 1 about here]
The conditions in Figure 1 reflect a very specific biological model. Our objective is to develop a statistical
method appropriate for this biological model. By using a method that tries to fulfill those conditions we can also
provide evidence that, for any particular case, the underlying biological assumptions behind this attempt are
inconsistent with the data or, in other words, the the assumptions embodied in Figure 1 are inappropriate. As
will be discussed later, our method is an attempt to map a particular biological model into a statistical method,
but other statistical approaches would be more appropriate if more complex biological models are regarded as
appropriate.
1.1 Limitations of alternative methods
A variety of approaches have been used to identify molecular signatures. A review is provided in the supple-
mentary material. Briefly, most methods return either a single signature component (e.g., Golub et al., 1999;
Hedenfalk et al., 2001; van Belle, 2002) which is a weighted average of a set of genes, or several signature
components (e.g., Antoniadis et al., 2003; Hastie et al., 2001a; Huang et al., 2003b; Ramaswamy et al., 2001;
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West et al., 2001) which are often obtained using dimension reduction techniques (e.g., principal component
analysis [PCA], partial least squares [PLS], sufficient dimension reduction) either on the complete set of genes
or on a preselected subset.
The most common problems of available methods are:
• Genes within signature components do not necessarily show tight coexpression: no method makes tight
coexpression a requirement to be fulfilled.
• The interpretation of components is very difficult for most methods that use PCA or PLS, since all the
genes to which PCA or PLS is applied have loadings on each component.
• The search for components in many PCA or clustering of genes methods is carried out without incorpo-
rating information from the dependent variable.
• Most methods are designed for a specific type of task (e.g., classification or survival, but not both) and
would be difficult to extend to other types of dependent variables.
Our objective in this paper is to propose a method that overcomes these problems. Specifically, our method
returns signature components of tight coexpression (and thus, signature components that should ease interpre-
tation) with good predictive performance. Although in this paper we focus on class prediction, our method can
be used with different types of dependent data (continuous, categorical, survival), and thus sets up a general
framework for finding gene expression signatures regardless of the type of dependent variable.
Based on the proposed operational definition of signatures (see figure 1), we first discuss the key elements
of our proposed method. Next, we evaluate its predictive performance and finally with discuss it relation with
other methods and problems of biological interpretability. Further details about the algorithm, evaluation of
recovery of signatures, and a longer review of alternative approaches are provided in the supplementary material.
2 Methods
2.1 Key elements of the proposed method
Our objective is to directly fulfill the conditions in figure 1. We start our search with a seed gene that will be the
skeleton of a signature component; this first signature component is found so that genes within the component
show tight coexpression and the prediction error is acceptable. We repeat this process (find seed gene for a
component and then obtain the whole component) greedily, until no further components are needed. The main
steps of the algorithm are shown in Figure 2. In this section we explain how the conditions in figure 1 can be
fulfilled and provide a geometrical interpretation of the algorithm.
[Figure 2 about here]
2.1.1 Fulfilling signature requirements
A common and simple way of characterizing a signature component is to use linear combinations (weighted av-
erages) of the genes that belong to that signature component (e.g., Ramaswamy et al., 2003; Rosenwald et al.,
2002; Shipp et al., 2002; West et al., 2001). Although we could characterize a signature component using several
different linear combinations of the genes of that component, most methods (but see Liu et al., 2002) charac-
terize a signature component or metagene using only one linear combination. A single metagene per signature
component simplifies interpretation, and is implicit in the requirement that each gene of a signature components
should show a strong correlation with the signature component.
Thus, to fulfill requirement one in figure 1, we can use Principal Component Analysis (PCA—which is closely
related to Singular Value Decomposition [SVD]). PCA yields “the best” representation (or “least distorting”
representation, in the least squares sense) of the original data (e.g., Jolliffe, 2002; Krzanowski, 1998; Morrison,
1990) in a subspace of reduced dimensions. The first PC is the best 1-dimensional representation of the original
genes of this signature component. If the genes of the signature component are tightly coexpressed, then each
of these genes should show a high correlation with the signature component, as we required above (this will also
mean that the percentage of variance in the original gene expression data explained by this first PC will be high
—see supplementary material). After running the procedure, each signature component will be made of tightly
coexpressed genes (we require that all the genes in a component show a correlation larger than a pre-specified
threshold of rmin).
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In contrast to some previous methods which use PCA or PLS over the complete set of genes, there is no need
for our method to return components which are uncorrelated or orthogonal: there is no biological argument
that requires that signature components be orthogonal, uncorrelated, or independent (see discussion). For ease
of interpretation we will additionally require that no gene belongs to more than one signature component. (In
other words, each gene in the original data matrix belongs to either one, and only one, signature component or
to none.)
The second and third requirements of figure 1 can be incorporated by adding new signature components
only if they result in a relevant reduction of prediction error, and retaining genes in a signature unless they
produce large increases in prediction error. In other words, we will penalize adding signature components, but
will try to obtain large signature components. The reason is that the search for molecular signatures is often
pursued to provide biological insights into coexpressed genes related to conditions and, therefore, minimization
of prediction error is not the only goal. Thus, if there are potential trade-offs between prediction error and
“biologically interpretable signatures”, the researcher should have the option of modifying the terms of this
trade-off flexibly.
2.1.2 Searching for signature components and a geometrical interpretation
Our objective is, thus, to maximize predictive performance using signature components that satisfy that the
correlation of each gene in a signature component with the signature component is larger than a given threshold.
However, the discussion so far does not indicate how to find the signature components and, given the dimen-
sionality of the problem, an exhaustive search for the optimal solution is not possible. Since we require that
each component be highly correlated with the genes of that component, we can start the search with genes that
have good predictive abilities on their own. Once we find an initial “seed gene”, we build an initial candidate
signature component by including all “promising genes”(e.g., all those with a minimum correlation with the seed
gene), and later reduce the signature component eliminating genes until the conditions of minimum correlation
with 1st PC (all genes have a correlation with the 1st PC > rmin) and predictive performance are met. (If this
elimination eliminates all genes except the seed gene, then, of course, the two requirements are met).
The method proposed here is a heuristic search that has an intuitive geometrical interpretation. We require
that each component be highly correlated (> rmin) with the genes in the component, which is equivalent to
saying that the vector of the component must have a similar direction as the vectors of each gene in variable space
(the space where subjects are the axes). Therefore, no matter which genes belong to a signature component,
the component will have a similar direction as any of its genes. Then, it seems reasonable to start the search
with the direction that has the best predictive ability, the seed gene; this seed gene is the single direction in
space that most contributes to separation of the groups in a classification problem; analogous for regression or
survival analysis. When we form the complete signature component, all other genes of the signature component
have directions that are similar to that of the seed gene. Together, all the genes of a signature component move
the direction slightly, but this shift is possibly towards directions that contribute more to separation of groups
(or that at least do not degrade the separation too much) and never moves us far away from the original seed
gene. This process is repeated until the addition of new signature components does not achieve any relevant
decrease in prediction rate, or until a maximum pre-specified number of signature components is reached. The
algorithm is shown in figure 2. Further details are given in the supplementary material.
2.1.3 Choice of underlying classifier
In this paper we will be dealing with a classification problem. Each signature component is used as a predictor
variable for a classifier. Of the available classification methods, we have used DLDA (diagonal linear discriminant
analysis), a version of linear discriminant analysis which assumes the same diagonal variance-covariance matrix
for all the classes (Dudoit et al., 2002), and NN (k-nearest neighbor, with k = 1), a simple non-parametric rule
that assigns a test sample to the class of the closest training sample (where closeness is measured using Euclidean
distance in the space whose dimensions are the signature components). KNN and DLDA have been repeatedly
shown to perform as well as, or better than, many competing methods with microarray data (Dudoit et al.,
2002; Romualdi et al., 2003). In addition, DLDA and KNN are simple to implement and interpret. Dudoit et al.
(2002) used an adaptive procedure to estimate the optimal number of neighbors to use with KNN; that can
be time consuming, and we have fixed K = 1, since this is often a successful rule (Hastie et al., 2001b; Ripley,
1996). As discussed in the supplementary material, other classifiers can be used.
3 Comparing predictive performance with established methods
Here we compare the predictive performance of our method with that of three well established methods, support
vector machines, KNN, and DLDA, using several“real data”sets. The supplementary material reports simulation
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studies that show that the suggested method can indeed recover signatures when they are present in the data.
Predictive performance is evaluated using 10-fold cross-validation (i.e., the complete algorithm shown in
Figure 2 is applied to each of the 10 “training sets”). This 10-fold cross-validation was repeated 20 times under
each condition. The error rates shown are not the CV error rates obtained in steps 1 and 5 of the signature
algorithm (see Figure 2), since those are biased down (see supplementary material); the error rates shown are
the error rates obtained from cross-validating the complete procedure.
Because an important parameter of our method might be rmin, the minimal absolute correlation between each
gene in a signature component and the signature component, we have evaluated the performance of the signature
method using a set of values of rmin that covers a“biologically interesting”range: {.60, .65, .70, .75, .80, .85, .90, .95}.
In addition, we have also examined the differences between using c1 = c2 = 1 compared to c1 = c2 = 0; the
first corresponds to the usual “1 se rule” and should lead to more interpretable results (c1 and c2 are related to
how much we penalize adding a new signature component and how much we penalize eliminating genes from
signature components; see details in supplementary material).
3.1 The data sets
Leukemia dataset From Golub et al. (1999). The original data, from an Affymetrix chip, comprises 6817
genes, but after filtering as done by the authors we are left with 3051 genes. Filtering and preprocessing is
described in the original paper and in Dudoit et al. (2002). We used the training data set of 38 cases (27
ALL and 11 AML) in the original paper (the observations in the “test set”are from a different lab and were
collected at different times). This data set is available from [http://www-genome.wi.mit.edu/cgi-bin/cancer/datasets.cgi]
and also from the Bioconductor package multtest ([http://www.bioconductor.org]).
Adenocarcinoma dataset From Ramaswamy et al. (2003). We used the data from the 12 metastatic tu-
mors and 64 primary tumors. The original data set included 16063 genes from Affymetrix chips. The data
(DatasetA Tum vsMet.res), downloaded from [http://www-genome.wi.mit.edu/cgi-bin/cancer/], had
already been rescaled by the authors. We took the subset of 9376 genes according to the UniGene mapping,
thresholded the data, and filtered by variation as explained by the authors. The final data set contains
9868 clones (several genes were represented by more than one clone); of these, 196 had constant values
over all individuals.
NCI 60 dataset From Ross et al. (2000). The data, from cDNA arrays, can be obtained from [http://genome-www.stanford.edu/sutech/download/nci60/index.html].
The raw data we used, which is the same as the data used in Dettling & Bu¨hlmann (2003); Dudoit et al.
(2002), is the one in the file “figure3.cdt”. As in Dettling & Bu¨hlmann (2003); Dudoit et al. (2002) we
filtered out genes with more than two missing observations and we also eliminated, because of small sam-
ple size, the two prostate cell line observations and the unknown observation. After filtering, we were
left with a 61 x 5244 matrix, corresponding to eight different tumor types (note that, as done by previ-
ous authors, we did not average the two observations with triplicate hybridizations). As in Dudoit et al.
(2002) we used 5-nearest neighbor imputation of missing data using the program GEPAS (Herrero et al.,
2003) (http://gepas.bioinfo.cnio.es/cgi-bin/preprocess); unlike Dudoit et al. (2002), however, we
measured gene similarity using Euclidean distance from the genes with complete data, instead of corre-
lation: Troyanskaya et al. (2001) found Euclidean distance to be an appropriate metric. Finally, as in
(Dudoit et al., 2002, p. 82) gene expression data were standardized so that arrays had mean 0 and vari-
ance 1 across variables (genes).
Breast cancer dataset From van Belle (2002). The data, from Affymetrix arrays, were downloaded from
[http://www.rii.com/publications/2002/vantveer.htm] (we used the files ArrayData less than 5yr.zip,
ArrayData greater than 5yr.zip, ArrayData BRCA1.zip, corresponding to 34 patients that developed dis-
tant metastases within 5 years, 44 that remained disease-free for over 5 years, and 18 with BRCA1 germline
mutations and 2 with BRCA2 mutations). As did by the authors, we selected only the genes that were
“significantly regulated” (see their definition in the paper and supplementary material), which resulted in
a total of 4869 clones. Because of the small sample size, we excluded the 2 patients with the BRCA2
mutation. We used 5-nearest neighbor imputation for the missing data, as for the NCI 60 data set. Fi-
nally, we excluded from the analyses the 10th subject from the set that developed metastases in less than
5 years (sample 54, IRI000045837, in the original data files), because it had 10896 missing values out of
the original 24481 clones, and was an outstanding outlying point both before and after imputation. The
breast cancer dataset was used both for two class comparison (those that developed metastases within 5
years vs. those that remain metastases free after 5 years) and for three group comparisons.
Therefore, we use three datasets in which the problem is classification into two classes (leukemia, adenocar-
cinoma, breast cancer), one dataset with a three class problem (breast cancer) and one dataset with an eight
class problem.
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3.2 The competing methods
We have used three methods that have shown good performance in reviews of classification methods with
microarray data (Dudoit et al., 2002; Romualdi et al., 2003).
Diagonal Linear Discriminant Analysis (DLDA) DLDA is the maximum likelihood discriminant rule, for
multivariate normal class densities, when the class densities have the same diagonal variance-covariance
matrix (i.e., variables are uncorrelated, and for each variable, its variance is the same in all classes). This
yields a simple linear rule, where a sample is assigned to the class k which minimizes Σpj=1(xj − x¯kj)
2/σˆ2j ,
where p is the number of variables, xj is the value on variable (gene) j of the test sample, x¯kj is the
sample mean of class k and variable (gene) j, and σˆ2j is the (pooled) estimate of the variance of gene j
(Dudoit et al., 2002). In spite of its simplicity and its somewhat unrealistic assumptions (independent
multivariate normal class densities), this method has been found to work very well.
K nearest neighbor (KNN) KNN is a non-parametric classification method that predicts the sample of a
test case as the majority vote among the k nearest neighbors of the test case (Hastie et al., 2001b; Ripley,
1996). To decide on “nearest”here we use, as in Dudoit et al. (2002), the Euclidean distance. The number
of neighbors used (k) is chosen by cross-validation as in Dudoit et al. (2002): for a given training set, the
performance of the KNN for values of k in {1, 3, 5, . . . , 21} is determined by cross-validation, and the k
that produces the smallest error is used.
Support Vector Machines (SVM) SVM are becoming increasingly popular classifiers in many areas, in-
cluding microarrays (Furey et al., 2000; Lee & Lee, 2003; Ramaswamy et al., 2001). SVM (with linear
kernel, as used here) try to find an optimal separating hyperplane between the classes. When the classes
are linearly separable, the hyperplane is located so that it has maximal margin (i.e., so that there is
maximal distance between the hyperplane and the nearest point of any of the classes) which should lead
to better performance on data not yet seen by the SVM. When the data are not separable, there is no
separating hyperplane; in this case, we still try to maximize the margin but allow some classification errors
subject to the constraint that the total error (distance from the hyperplane in the “wrong side”) is less
than a constant. For problems involving more than two classes there are several possible approaches; the
one used here is the “one-against-one” approach, as implemented in libsvm Chang & Lin (2003). Reviews
and introductions to SVM can be found in Burgues (1998); Hastie et al. (2001b).
For each of these three methods we need to decide which of the genes will be used to build the predictor.
Based on the results of Dudoit et al. (2002) we have used the 200 genes with the largest F -ratio of between to
within groups sums of squares. Dudoit et al. (2002) found that, for the methods they considered, 200 genes as
predictors tended to perform as well as, or better than, smaller numbers (30, 40, 50 depending on data set).
We evaluated predictive performance using 10-fold cross-validation; the results shown are from 20 replications
of the 10-fold cv process. In all cases, cross-validation includes gene selection (Ambroise & McLachlan, 2002;
Simon et al., 2003); in other words, for the three competing methods and the signature algorithm the selection
of genes is carried out within each of the 10 “training sets” of the cross-validation. Thus, we insure that the
subjects for which prediction is performed have not been used for the gene selection process.
4 Results
Predictive performance is shown in Figure 3. Predictive performance changes very little from using DLDA vs.
NN, or setting c1 = c2 = 1 vs. c1 = c2 = 0; figures for four combinations of classifier and values of c1, c2 are
shown in the supplementary material. Comparing c1 = c2 = 1 with c1 = c2 = 0 (see Figures in supplementary
material) does not show any relevant differences in predictive performance; of course, there are differences in the
outcome because, not surprisingly, using c1 = c2 = 0 tends to result in more signature components of smaller
numbers of genes per component, and higher correlations between components.
[Figure 3 about here]
[Table 1 about here]
With respect to rmin, except for the NCI data set, and slightly for the Breast cancer with 3 classes data
set, changes in rmin have little effects on predictive performance. In Table 1 we show the median number of
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components, median total number of genes in a signature, and median average number of genes per component
obtained in 200 bootstrap runs using c1 = c2 = 1 with rmin = 0.85 and rmin = 0.6, and using NN as the
classifier (see also section 4.1). It can be seen that changes in rmin do affect the outcome in terms of number of
number of genes per component. These results seem to indicate that choice of rmin can probably be guided more
by interpretability concerns (whether we want larger signature components of looser coexpression or smaller
signature components of tight coexpression) than by concerns over predictive ability.
Finally, the performance of the signature method is only slightly worse than that of the three competing
classifiers, except for the NCI data set. As seen in Table 1, most of the signatures, specially with rmin = 0.85,
used very few components of very few genes each (compared to the use of 200 genes for the competing classifiers);
thus, the predictive performance is achieved using a very small number of genes and thus potentially facilitating
a simple biological interpretation. In the case of the NCI data set, there are eight classes with only 61 samples,
and in most cases the signature component only returned between 1 and 3 components. Probably the forward
sequential addition of components in the signature method has affected negatively the predictive capabilities,
because any single addition was most likely incapable of resulting in a large enough decrease of prediction error
to justify further addition of components (in contrast to using, directly, 200 genes as predictors).
4.1 Stability of results
To evaluate the stability of results, we rerun the complete procedure on all data sets using the bootstrap
(Davison & Hinkley, 1997; Efron & Tibshirani, 1993) with 200 bootstrap samples, similar to what Efron & Gong
(1983) do to evaluate a complex fitting procedure. We run the procedure for settings of c1 = c2 = 1 with
rmin = 0.85 and rmin = 0.6, and using NN as the classifier. The results are shown in Table 2. The bootstrap
results indicate that, when using a high value of rmin we rarely obtain similar solutions repeatedly; some data
sets, however, seem to yield more stable solutions (e.g., Leukemia data sets) and, not surprisingly, if the rmin
criterion is set to less stringent values, results tend to be more repeatable.
[Table 2 about here]
5 Discussion
5.1 Similarities and differences with other methods
Our method is unique because it simultaneously searches for sets of genes that are tightly coexpressed and will
lead to good predictive performance. The search for the sets of genes is carried out using the information from
the dependent variable (at the first stage —when selecting the seed gene—, and at the pruning stage of reducing
the signature component —when genes that lead to decreased predictive performance are eliminated from the
signature component —; see figure 2).
One important difference between our proposed method and most previous approaches that use PCA is that,
by performing PCA only on subsets of genes, our method returns signature components where genes show tight
coexpression. Because returned components are not orthogonal, and simple components are an explicit goal,
our approach is actually closer to some ideas implemented in SAS’s PROC VARCLUS, which is similar to factor
analysis with oblique rotation and can be used to obtain clusters of variables, of relatively simple interpretation,
to be further used in model building Nelson (2001); SAS Insitute (1999); see also Harrell (2001).
Using PCA on subsets of genes, instead of the complete set of genes is crucial because it makes interpre-
tation easier and allows for subsets of tight coexpression. Simple PCA and related methods (Jolliffe, 2002;
Rousson & Gasser, 2003; Vines, 2000) as well as SAS PROC VARCLUS also try to achieve components of tight
coexpression, but many of these approaches cannot be applied with p≫ n, and all of them carry out the PCA
without using the information from the dependent variable, which in our case is a fundamental requirement since
the sets of genes with tightest coexpression would be irrelevant for our purposes if they are not related to the
dependent variable we are trying to model. This difference in objectives is also evident because our aim is not
to explain the most variance in the genes (as in most simple PCA approaches) nor maximize variable explained
across all clusters (such as in PROC VARCLUS). Overall summarization of information is not important for our
problem, because we are interested in prediction, and we often have the suspicion that most of the genes in the
array are not related to the outcome variable. Finally, our approach can result in signature components which
are correlated (sometimes strongly), but this is not inherently a problem because there is no biological reason
to suggest that the underlying biological causes or factors ought to be independent or uncorrelated; moreover,
if the true underlying causes are not orthogonal, using a method such as PCA can lead to interpretational
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and conceptual difficulties because each biological cause will be spread over several orthogonal components
(Houle et al., 2002): non-orthogonal biological causes are inconsistent with procedures such as PCA and PLS.
Bayesian classification trees using the 1st PC from gene clusters (Huang et al., 2003a) and block PCA
(Liu et al., 2002) also used PCA on subsets of genes, instead of the complete set of genes. In both cases their
subsets of genes were obtained using criteria that did not make any use of the information from the dependent
variable. In addition, in Huang et al. (2003a) the metagenes are not necessarily of subsets of tightly coexpressed
genes. In Liu et al. (2002) there is an explicit criterion of % variance accounted for, but often the number of
components used to summarize a subset of genes is too large to allow for easy interpretation (11 to 16 principal
components).
Supervised harvesting of expression genes (Hastie et al., 2001a) also works with clusters of subsets of genes,
which are then used in a predictive model. As before, however, the clustering is carried out without using
information from the dependent variable; even if the selection of which subsets or clusters to use in the model
uses the information from the dependent variable, the very first step of clustering genes does not, and can
therefore be unable to recover sets of tightly coexpressed genes that are good predictors. Finally, the “Wilma”
and “Pelora”methods (Dettling & Bu¨hlmann, 2002, 2004) do use the information from the dependent variable
in the formation of clusters of genes; however, there is no explicit objective of achieving tight gene coexpression
within clusters and thus, how tightly coexpressed genes are in each metagene cannot be specified in advance; in
addition, Wilma weights each gene equally within a cluster (only possible weights are +1 and -1) whereas we
use PCA on unscaled genes, thus allowing genes to play a different role in the specification of the direction of
the signature component (genes with larger among-subject variance play a more important role in determining
direction).
The rest of the alternative methods differ strongly from our proposed method, either because they do not
return subsets of genes but components with loadings from all genes (e.g., PLS based methods), or return
subsets of genes where there is not requirement of tight coexpression (e.g., weighted gene voting, Golub et al.,
1999).
After gene selection and dimension reduction (i.e., the use of only the 1st PC, that collapses all the informa-
tion from the genes of a signature component onto one dimension), the predictive model of our choice is fitted.
In this sense, the method as presented here is “just” a DLDA or NN that uses signature components instead of
genes as the predictors. The choice of DLDA and NN was made based on published results that showed their
excellent performance with microarray data. In particular, Dudoit et al. (2002) showed that other forms of
discriminant analysis tended to perform much worse because of the small ratio sample size/parameters needed
to estimate covariances and different variances per group; however, since in most cases our method returns just
a few signature components, other types of discriminant analysis that use the information from the covariance
of the predictors (e.g., linear discriminant analysis and quadratic discriminant analysis) might prove useful.
5.2 Coexpression: across-group and within-group
The algorithm can include in a signature component genes that show no correlation within groups but that
show correlation among groups because they are far apart in the multidimensional space, and the correlation
coefficient is computed across the whole, pooled, sample. The algorithmmight even include in the same signature
component genes that have very different patterns of correlation in different groups, if they still show sufficiently
strong correlation over the pooled sample.
To our knowledge, this issue has not been explicitly addressed in any other approach to the signature
problem (see reviews in supplementary material). However, probably the most biologically relevant components
are those where there is strong correlation within groups, because this is a more reliable indicator of coordinated
expression.
A possible solution is, for example, to only accept results for a signature component if a principal component
analysis over the pooled sample after centering the data with respect to the group means yields a relevant first
eigenvalue; for added robustness, we might want to use the trimmed mean. This approach, however, does not
directly address if there are different multivariate orientations in different groups of subjects, and how these
orientations within-group relate to the across-group orientation. In particular, the case where several groups
not only have the same first principal component, but are lined up along a common axis, known as “allometric
extension” (Bartoletti et al., 1999; Hills, 1982), might constitute the most natural type of signature component.
Krzanowski (see reviews and summary in Jolliffe, 2002; Krzanowski, 1998) has proposed a method to directly
compare the subspaces defined by the principal components of each of the groups. In our case, as we only use
the first principal component of a set of genes to define a signature component, for each signature component
we can compare the first principal component of each group. An example using the NCI 60 data set is shown
in the supplementary material. This method only compares the orientation of the principal components (the
eigenvectors) but does not compare the location of the multivariate means. The EDDA (Bensmail & Celeux,
1996) and common principal components (Flury, 1988) approaches provide frameworks to examine differences
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among covariance matrices of particular interest in the context of discrimination among groups. Nevertheless,
it must be remembered that biological interpretation of results is not always straightforward, specially when
the underlying biological factors are not orthogonal (Houle et al., 2002), and that we need to asses the need for
robust methods (Boente et al., 2002) and power issues related to the small sample sizes common in microarray
data. We are currently investigating some of these issues; however, in the presence of the difficulties associated
with interpretation, low statistical power, and possible lack of robustness to outlying observations, right now
the best recommendation could be to conduct an examination of patterns of within vs. among coexpression for
the returned signatures.
5.3 Stability and biological relevance of signatures
Our method follows from an operationalization of signatures and signature components (figure 1). If the ideas
embodied in figure 1 have empirical support, then it might be possible to build good predictive models using
just a few, very specific biological features that can be related to alterations on particular pathway. Our method
is unique in this regard because it returns only a few signature components where genes within each component
are tightly coexpressed.
On the other hand, our method can indicate that the data are inconsistent with the ideas behind figure 1: if
the signature components show high instability, this is evidence that very different models can be obtained from
the data. Widely different models from a reasonably large data set cast doubt on the idea that a few, easily
interpretable, signature components strongly correlated with the expression of a few key genes are associated to
the clinical outcome of interest. In the context of building predictors from gene expression data, Somorjai et al.
(2003) (see also Zhang et al., 2003) have emphasized that this non-uniqueness leads to interpretational difficulties
and should make researchers skeptical about the biological relevance of any set of predictors; moreover, they
explain how this non-uniqueness can arise from dataset sparsity. Of course, both of these issues are relevant to
the present proposed methodology. None of the data sets examined in this paper yield stable signatures when we
use stringent criteria of gene coexpression (see 4.1 and Table 2 with rmin = 0.85), although some of the data sets
are somewhat stable from run to run when the rmin is set to small values (but other data sets show signatures
that vary widely from run to run). These results add to the above references in the sense that biological
interpretation should be carried out very cautiously, and emphasize the difference between attempting to build
good predictors and attempting interpretation (see also Breiman, 2001). More relevant to the current work, the
present results indicate that simple models of molecular signatures warrant further critical scrutiny, and that it
might be extremely hard to identify molecular signatures from such sparse data sets (see Rhodes et al., 2004,
for a meta-analysis attempt to identify stable “signatures”).
We must recognize that these results are preliminary for two main reasons. First, establishing that two or
more signature components are different probably requires additional information besides the identities of the
genes; for instance, information from Gene Ontology, or known participation on certain regulatory networks.
Second, we have used two different rmin thresholds, but it is unclear what constitute “biologically reasonable”
patterns of covariation between genes that are to belong to the same signature component. Nevertheless, even if
preliminary, these results emphasize the need for further work in the operationalization and explicit definition of
what we mean by molecular signatures, careful consideration of the stability of results, and critical assessment
of the sample sizes need to reliably identify molecular signatures.
5.4 Alternative statistical methods for alternative biological models
As mentioned in the introduction, we started by trying to clarify, conceptually, what is often understood
by molecular signature (see Figure 1), and then devised a statistical method to fulfill those requirements.
The biological model underlying the suggested method is one where most of the genes are not relevant for
prediction, relevant genes are involved in one and only one signature component (i.e., non-overlapping signature
components), and the signature components are common, and have similar covariance matrices, in different
groups.
However, other biological models are plausible, and for those biological models other statistical methods
would be more appropriate. The simultaneous clustering and classification approach in Jo¨rnsten & Yu (2003)
could be extended by placing restrictions on the covariance matrix (i.e., require a minimum correlation between
genes) but possibly allowing for different covariance matrices among groups; thus, we could address directly
issues of different across vs. within-group correlations (see section 5.2), within a formal inferential framework.
Biological models where signature components are not common and/or do not behave similarly in different
groups could be investigated using modifications of the Plaid model of Lazzeroni & Owen (2002) (see also
Turner et al., 2004). In addition, genes with the highest correlation need not be the best candidates for being
in the same biological pathway; activity in a pathway might just require that precursor genes get activated,
but once a threshold is reached, it might not be very important by how much the threshold is exceeded. This
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type of behavior could preclude strong correlation between genes that belong to the same pathway. This can
be modelled building upon the latent class methods of Parmigiani and colleagues (Garrett & Parmigiani, 2003;
Parmigiani et al., 2002; Scharpf et al., 2003), where signature components are based on under-, over- or baseline
expression (instead of expression levels). Work along these lines is currently in progress in our group.
5.5 “Just” dimensional reduction?
Even if the current method fails to identify stable features that can be associated to molecular signatures, it can
be a useful dimension reduction tool. Difficulties associated with a simple mapping of the returned “signature
components” to pathways, and problems derived from instability of the found components also affect any other
of the existing alternative methods. Thus, in the presence of instability of results, it is more appropriate
to regard this method as dimension reduction tool that could lead to simple biological interpretation. The
simple biological interpretation could be helped not only because of the coexpression of the genes that make
a signature component, but also because the dimension reduction performed is quite remarkable compared to
other methods (the number of signature components and genes returned is very small for the five data sets
examined; see Results) with, at most, only a slight decrease in predictive performance. Moreover, the user
can control the relative trade-offs between predictive performance and potential interpretability of results (e.g.,
coexpression of sets of genes) by changing the rmin parameter (note that if rmin = 1 the method becomes
essentially either DLDA or NN with forward addition of genes to the model). This flexible modification of
the trade-offs between prediction error and interpretability is of great importance in methods that are largely
exploratory and oriented towards providing “biologically interpretable” output; in other words, methods for
which minimization of prediction error should not be the only goal.
6 Conclusions
The most common methods for finding signatures present several deficiencies that do not allow them to return
signatures and signature components that fulfill basic biological requirements. After suggesting an operational
definition of signature and signature components, we have developed a method that follows directly from what
are often considered as the biologically relevant signature characteristics. The method developed returns signa-
ture components of tightly coexpressed genes and thus can facilitate biological interpretation. In this paper we
have applied the method to classification problems, but this approach in fact sets up a framework that allows us
to find signatures regardless of the type of dependent variable. Extension to use other classifiers is straightfor-
ward and it should also be easy to incorporate other types of dependent variables to allow, for example, survival
analysis. We have also shown that the predictive performance of our method is comparable to that of state of
the art methods. Finally, our method not only could facilitate mapping pathological alterations to a few, tightly
coexpressed sets of genes, but can also provide evidence that the underlying biological assumptions behind this
attempt are inconsistent with the data. In the five data sets analyzed, our results suggest that identification of
molecular signatures is questionable under this simple model. These results emphasize the needed for further
work on the operationalization of the biological model and the necessity of critical assessment of the stability
of putative signatures.
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rmin = 0.85 rmin = 0.6
Data set Total
genes
# Compo-
nents
Mean
Genes/Component
Total
genes
# Compo-
nents
Mean
Genes/Component
Leukemia 6 1 5 52.5 1 50
Breast cancer (2 classes) 2 2 1 10 2 3.875
Breast cancer (3 classes) 6 2 2.5 63.5 2 33.25
Adenocarcinoma 5 1 3 45.5 1 31.5
NCI 60 4 2 1.67 16 2 7.1
Table 1: Median values from 200 bootstrap runs for total number of genes in signatures, number of signature
components and average number of genes per component.
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rmin = 0.85 rmin = 0.6
Data set Genes present Genes present
at least % runs at least % runs
50 20 10 50 20 10
Leukemia 0 7 15 7 80 179
Breast cancer (2 classes) 0 0 9 0 0 43
Breast cancer (3 classes) 0 0 3 0 51 246
Adenocarcinoma 0 0 3 0 45 270
NCI 60 0 0 0 0 0 6
Table 2: Stability of results using the bootstrap, with 200 bootstrap iterations. Values shown are the number
of genes that are returned, as members of a signature component, in at least those many bootstrap runs.
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1. Genes of a signature component should show tight coex-
pression. We can make this more explicit by requiring that
each gene of a signature component should show a strong
correlation with the signature component.
2. For a given classification/prediction problem only a few sig-
nature components should be needed to obtain reasonable
predictive performance.
3. Signature components could have many genes; addition-
ally, it often seems more desirable to include a gene in a
signature component even if it does not belong to that sig-
nature, than to exclude a gene that does belong to that
signature.
4. The same genes are used for a signature component over
all samples (i.e., the signature components are the same for
all groups).
Figure 1: Requirements of signatures and signature components (see text for details).
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1. Find the seed gene for a signature component:
(a) Seed gene is gene with smallest cross-validated (CV) predic-
tion error among available genes. (The CV prediction error is
obtained using as predictive model the chosen predictor [e.g.,
DLDA], including all previous signatures, if any).
(b) If CV prediction error < (CV prediction error of the previous
signature - c1 standard error), continue; otherwise, terminate
signature finding.
2. If signature component = 1, eliminate all genes with (resubstitu-
tion) prediction error > prediction error from always betting on
the most frequent class.
3. Build an initial signature with all the genes j where
abs(cor(genej, seed.gene)) ≥ rseed.
4. Obtain the signature component as the 1st PC of a PCA on the
initial signature.
5. Reduce signature component:
(a) Eliminating, one by one, from the signature the gene with
the smallest absolute correlation with the seed gene, until
abs(correlation(xpri,j,pri)) > rmin is met.
(b) Eliminate, one by one, any gene for which its exclusion from
the signature component leads to a CV prediction error < last
prediction error - c2 s.e.(prediction error).
6. Exclude from further consideration all genes that belong to the
signature component just build.
7. Return to 1. until no further components are needed.
Figure 2: Basic steps of the signature algorithm.
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Figure 3: Predictive performance, as a function of rmin, of the signature method using NN as classifier and
comparison with SVM, KNN, and DLDA. Figures based on 20 replicates of the 10-fold-CV procedure. Results
for c1 = c2 = 1.
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